Biparatopic antibodies and biparatopic alternative scaffolds are proteins that can simultaneously bind two distinct epitopes, and as such are promising formats for the development of next-generation antibody therapeutics. By design, biparatopic proteins have high avidity and can bridge between epitopes in an intra-or intermolecular manner to form diverse immunocomplexes. Some biparatopic proteins can be efficiently internalized into cells, which may be useful for the targeted delivery of therapeutic molecules into cells. In addition, biparatopic proteins can also lock the conformation of membrane proteins to exert an agonist or antagonist effect. Here, we review the development and characteristics of biparatopic proteins and examine how they differ in terms of antigen-binding efficiency, immunocomplex formation and biological activity compared with conventional monoparatopic proteins.
Monoclonal antibodies target specific proteins and are therefore useful for development as targeted therapies. Small protein domains-such as natural camelid-derived single-domain antibodies (VHHs or Nanobodies) [1, 2] and artificial library-derived alternative scaffold proteins (e.g., Affibodies or designed ankyrin repeat proteins [DARPins]) [3, 4] -have also been developed as alternatives to conventional immunoglobulins to circumvent issues that hamper the production of full-size immunoglobulins. These monoclonal antibodies and small protein domains are usually developed as monoclonal polypeptides with specificity for a single antigen epitope and are therefore referred to as 'monoparatopic proteins'.
Recently, biparatopic proteins derived from two different antibodies or alternative scaffold proteins have been developed. Biparatopic proteins contain two antigen-binding domains (i.e., paratopes) that bind to different antigen epitopes. Biparatopic antibodies (BpAbs) have been known for almost 30 years [5] , but it was not until recently that technological advances [6] allowed the development of biparatopic antibodies with sufficient quality for development into drugs. Currently, two BpAbs against human epidermal growth factor receptor 2 (HER2) are undergoing clinical trial, with one being developed as an antibody-drug conjugate [8, 9] and the other being developed as both a naked antibody and an antibody-drug conjugate [10, 11] . In addition, one biparatopic DARPin against HER2 is also undergoing clinical trial [12] . Biparatopic proteins have several advantages over monoparatopic proteins. Here, we review the development and characteristics of biparatopic proteins, and discuss the future perspectives of this class of proteins as therapeutic agents.
Overall, the advantages of biparatopic proteins compared with monoparatopic proteins are their increased binding avidity, their ability to form immunocomplexes that monoparatopic proteins cannot, and their ability to lock the conformation of membrane proteins to exert secondary activities.
Increased Binding Avidity of Biparatopic Proteins
The strength of the interaction between an antibody and its antigen depends mainly on the antibody's affinity and avidity for the antigen. Affinity is the ability of an antibodybinding domain to form a 1:1 complex with a target epitope and is generally dependent on the formation of non-covalent bonds such as hydrogen bonds and cation-π interactions between the antibody and the antigen [13] . In contrast, avidity is the accumulation of multiple affinities; that is, avidity, at least partly, describes the simultaneous binding of two (or more) antigen-binding units and the associated increased opportunity for rebinding of dissociated units. Avidity depends on the local concentration of antigen and the macromolecular structure of both the antibody and antigen molecules [14, 15] . For monomeric alternative scaffold proteins and fragment antibodies, generation of biparatopic proteins is an extremely efficient way of increasing avidity. Thus, a large number of these proteins have been developed as biparatopic agents [12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , which is not as important with conventional antibodies because they are already bivalent [5, 7, 8, 10, [30] [31] [32] [33] [34] [35] [36] [37] .
Biparatopic antibodies and scaffold proteins have improved avidity compared with their monoparatopic analog because they usually contain binding units that do not compete with each other. Previously, our group reported the development and characterization of monoparatopic and biparatopic dimeric single-chain variable fragments (scFvs) against the tetrameric membrane antigen roundabout homolog 1 (ROBO1) [36] . Interaction of ROBO1 with the different domains of the antigen was strongest for the biparatopic scFvs ( Table 1 ). The improved avidity of the biparatopic scFvs over the monoparatopic analog was likely because the relative position of the epitopes allowed for efficient simultaneous binding. Similarly, several other groups have reported that biparatopic proteins show stronger interaction compared with the monoparatopic analog ( Table 1 ). Among them, biparatopic anti-beta-Klotho antibody showed 5-fold improved interaction from the stronger one (Ab1-Ab1) between the two of monoparatopic antibodies of the same structure (Table 1 ) [27] . However, some biparatopic proteins that show weaker interactions than the monoparatopic analog have been reported [18, 29] , and these weaker interactions are likely because of a lack of dynamic reorganization of the membrane-bound antigen molecules, which is required for strong binding.
Slow dissociation is a characteristic of most of the biparatopic proteins developed to date (Table 1) . Indeed, a theoretical model has shown that bivalent interactions often result in longer residence time in the bound state [15] . Since the two binding units of biparatopic proteins do not compete, the probability of simultaneous binding occurring is increased, and dissociation is slowed compared with the monoparatopic analog. For example, our biparatopic scFvs against ROBO1 showed 1.7-times slower dissociation compared with the monoparatopic analog [36] . Similarly, Affibodies against vascular endothelial growth factor receptor 2 (VEGFR2) have been reported with an 19-or 14-fold slower dissociation rate compared with the monoparatopic analog [19] . Because slower dissociation is associated with longer-lasting therapeutic activity, the slow dissociation of biparatopic proteins makes them promising leads for development as therapeutic agents with long-lasting effects.
Immunocomplex Formation and Biological Activities
One unique feature of BpAbs is that after binding to antigens they can form bridging structures ( Fig. 1 ). If the two epitopes bound by the biparatopic protein are distant enough, and the antigen-binding domains do not compete with each other, both intramolecular and intermolecular bridging between epitopes are possible ( Fig. 1 ). Intramolecular bridging results in a complex with a 1:1 antibodyantigen complex ratio, whereas intermolecular bridging results in an equimolar complex of variable size, which can potentially be very large.
One subtype of BpAbs bridge the two epitopes inside the single antigen molecule intramolecularly (BpAb1-3 in Fig. 1 ) and are also termed as chelating antibodies in a few literatures [35, 38] . Two antigen-binding domains of this subtype of BpAbs binds simultaneously to the different epitopes of the same antigen molecule. The initial report of a chelating antibody against hen egg lysozyme showed more than a 10-fold improvement in affinity compared with the respective scFvs [35] . Avidity of biparatopic Affibody is maintained also for the membrane protein VEGFR2 [19] . In the studies of chelating antibodies against hen egg lysozyme, high affinity was reported only upon limited linker length between the scFvs [38, 39] , and the structure of the immunocomplex by these BpAbs should be strictly designed. Because a long linker is not always effective [15, 39] , epitope selection for intramolecular bridging is limited in the combinations of epitopes with specific distance on the surface of antigen as discussed elsewhere [23, 35] . It is also difficult for this type of BpAb to form immunocomplexes that provoke interaction-associated effects (see below). Thus, improved avidity is likely the only advantage this subtype of biparatopic proteins have over monoparatopic antibodies.
Most other BpAbs can bridge between antigen molecules to form intermolecular crosslinks (BpAb1-2 in Fig. 1) , which can sometimes result in the formation of huge immunocomplexes, as has been reported for BpAbs that are more than bivalent (e.g., tetravalent) [8, 9, 33] . Intermolecular crosslinks can be formed with both soluble proteins and membrane proteins. For soluble secreted proteins, the formation of large BpAb immunocomplexes enables clearance of the antigen from the blood, mediated by Fcγ receptors [30, 33] . For membrane proteins, immunocomplex formation can lock the proteins in an immunologically active state and enhance effector effects, such as the complement-dependent cytotoxicity of tumor-targeting antibodies [26] .
Intermolecular crosslinking of membrane proteins by BpAbs can also result in secondary effects such as internalization of the antigen or in agonist or antagonist effects (Fig. 2) . For example, intermolecular crosslinking of antigen molecules increases the density of the antigen, inducing density-dependent events such as endocytosis ( Fig. 2A) [29] , which can lead to antigen degradation and downregulation of disease-related signaling, such as in the cases of epidermal growth factor receptor (EGFR), HER2, and MET kinase [7, 16, 20, 34] . Such internalization may be useful for delivering antibody-drug conjugates into cells, and a few BpAb-drug conjugates against HER2 are currently undergoing clinical trials [8, 11] . In addition, some biparatopic proteins can lock the structure of an antigen, resulting in structure-dependent effects such as agonism or antagonism (Fig. 2B, 2C) . For example, a biparatopic DARPin that locks HER2 in its inactive form via intermolecular crosslinking has been reported [23] . Similarly, there are reports of biparatopic proteins with antagonist activity against LRP6 [31] , inverse agonist activities against chemokine receptors [17, 22] , and agonist activity against fibroblast growth factor 21 [27] . Although further elucidation of the mechanisms underlying these activities is needed, diverse function is generated by this subtype of biparatopic proteins. Analytical methods used to determine the parameters. BLI, biolayer interferometry; SPR, surface plasmon resonance; Cell ELISA, enzyme-linked immunosorbent assay using antigen-expressing cells. Fig. 1 . Schematic representation of the two types of immunocomplexes that can form between biparatopic proteins and antigen (yellow). Left: When a biparatopic antibody (BpAb1-2) is generated from a certain combination of two monoclonal antibodies (mAb1 and mAb2), intermolecular crosslinking occurs, resulting in the formation of large repeating immunocomplex with an equimolar antibody-antigen ratio. Right: Alternatively, when a biparatopic antibody (BpAb1-3) is generated from another combination of two monoclonal antibodies (mAb1 and mAb3), intramolecular bridging occurs, resulting in the formation of a 1:1 antibody-antigen immunocomplex. Which structure forms depends on the relative position of the epitopes and the specific structures of the biparatopic protein and antigen.
As described above, intermolecular crosslinking by biparatopic proteins can be used to induce a wide range of physiological effects. However, for efficient development of biparatopic proteins with such physiological effects, efficient paratope selection is important. Recently, a combinatorial approach was used to develop biparatopic DARPins against MET [16] . In this approach, multiple DARPins were designed with specificity for different MET domains, and then the most promising were combined; several DARPin combinations were found to have biparatopic activity resulting in the downregulation of MET. Such a combinatorial approach may be useful for accelerating the development of BpAbs and biparatopic scaffold proteins.
Conclusion
BpAbs and biparatopic alternative scaffold proteins have two main advantages over monoparatopic analogs: they have high avidity, and they can undergo intra-and intermolecular bridging. Intermolecular crosslinking can enhance internalization of the BpAb into cells, which suggests that BpAbs may be useful for development as targeted antibody-drug conjugates. Other mechanisms including agonist or antagonist effects are also expected. Currently, many biparatopic proteins have been generated against target molecules for which antibody therapies have already been developed (e.g. EGFR and HER2). However, because biparatopic proteins have novel functions compared with monoparatopic proteins, we can expect the development of biparatopic proteins against new target molecules, such as membrane proteins, that are not effectively targeted with current monoclonal antibody technology due to limitation in the structure of antibody-antigen macromolecular complex. Additionally, use of an appropriate scaffold protein enables fusion of a greater number of antigen-binding domains (e.g., triparatopic [7] ) that are more promising in efficient binding and crosslinking. Design of biparatopic proteins is not straightforward, for example in selection of appropriate paratopes and of the structure optimized for large-scale production. In case of biparatopic alternative scaffold proteins, fast clearance by absence of Fc needs to be solved. Despite these challenges, we hope that further development of biparatopic proteins as a novel modality within the field of antibody therapeutics will provide us with many innovative drugs. Fig. 2 . Simplified schematic representation of various secondary activities exerted by biparatopic agents after binding to membrane proteins (yellow). A) Biparatopic agents can form crosslinks between one another to form a high-density immunocomplex that is then internalized by cells via a mechanism such as endocytosis. This approach can be used to downregulate antigen presentation or deliver a drug conjugated to the biparatopic agent into a cell. B) Biparatopic agents can lock the structure of antigen molecules in an inactive state, resulting in an antagonist or inverse agonist effect. C) Biparatopic agents can lock the structure of antigen molecules in their active state, resulting in an agonist effect.
